Cai G, et al. - Researchers examined the link between hematologic markers and death and adverse events among patients who received neoadjuvant chemoradiotherapy (nCRT) for esophageal squamous cell carcinoma (ESCC). Retrospectively, enrollment of 311 patients with ESCC managed with nCRT from 2012 to 2014 was performed. The participants were observed for a median span of 22 months. Independent factors to predict five-year overall survival, in multivariate analysis, were: smoking history, Eastern Cooperative Oncology Group performance status, invasion depth, lymph node metastasis, platelet to lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). Overall, in this patient population, SII and PLR were identified as independent indicators to predict prognosis. For the prediction of grade ≥ 3 hematologic toxicity, a lower neutrophil to lymphocyte ratio at baseline was identified as an independent indicator.